Ovarian function and disease activity in patients with systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 26, Issue 3, 2008, Pages 436-441

  Shabanova, Sabina S ^a,c   Ananieva, Lidia P ^a   Alekberova, Zemfira S ^a   Gusov, Igor ^b  

^a V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^b Immunology and Reproduction Center   (Russian Federation)

^c NONE   (Russian Federation)

Author keywords

Disease activity; Ovarian function; Systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE; ESTRADIOL; FOLLITROPIN; GLUCOCORTICOID; LUTEINIZING HORMONE; PROGESTERONE; PROLACTIN;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ACTIVITY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GYNECOLOGICAL EXAMINATION; HUMAN; HYPERPROLACTINEMIA; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MENSTRUATION DISORDER; OLIGOMENORRHEA; OVARY FUNCTION; OVARY INSUFFICIENCY; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; CASE-CONTROL STUDIES; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; FOLLICLE STIMULATING HORMONE; GLUCOCORTICOIDS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUTEINIZING HORMONE; MENARCHE; MENSTRUATION; MIDDLE AGED; OLIGOMENORRHEA; OVARY; PROLACTIN; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 48949117139     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Mc MURRAY RW, MAY W: Sex hormones and systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2100-10.
2. GORBY H, BUTTS C, STERNBERG EM: Neuroendocrine immune interactions: Principles and relevance to systemic lupus erythematosus. In WALLACE JJ, HAHN BH (Eds.): Dubois' Lupus Erythematosus. 7th ed., Philadelphia, Lippincott Williams & Wilkins, 2007: 286-98.
3. DUNN AJ: Cytokine activation of the HPA axis. Ann N Y Acad Sci 2000; 917: 608-17.
4. STERNBERG EM: Neuroendocrine regulation of autoimmune/inflammatory disease. J Endocrinol 2001; 169: 429-35.
5. CUTOLO M, BIJLSMA JW, LAHITA RG, MASI AT, STRAUB RH, BRADLOW HL: Altered neuroendocrine immune (NEI) networks in rheumatology. Ann N Y Acad Sci 2002; 966: xiii-xviii.
6. CUTOLO M, STRAUB RH, BIJLSMA J: Neuroendocrine-immune interactions in synovitis. Nat Clin Pract Rheumatol 2007; 3: 627-34.
7. CUTOLO M, SULLI A, PIZZORNI C, CRAVIOTTO C, STRAUB RH: Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis. Ann N Y Acad Sci 2003; 992: 107-17.
8. HARBUZ MS, CHOVER-GONZALEZ AJ, JESSOP DS: Hypothalamic-pituitary-adrenal axis and chronic immune activation. Ann N Y Acad Sci 2002; 992: 99-106.
9. VAN ROSSUM EF, LAMBERTS SW: Glucocorticoid resistance syndrome: A diagnostic and therapeutic approach. Best Pract Res Clin Endocrinol Metab 2006; 20: 6-26.
10. BUYON JP, WALLACE DJ: The use of exogenous estrogens, endocrine system and urogenital tract. In WALLACE JJ, HAHN BH (Eds.): Dubois' Lupus Erythematosus, 6th ed., Philadelphia, Lippincott Williams & Wilkins, 2002: 821-41.
11. GONZALEZ-CRESPO MR, GOMEZ-REINO JJ, MERINO R et al.: Menstrual disorders in girls with systemic lupus erythematosus. Br J Rheumatol 1995; 34: 737-43.
12. LIM GS, PETRI M, GOLDMAN D: Menstruation and systemic lupus erythematosus (SLE): a case-control study. Arthritis Rheum 1993; 36: Abstract R23.
13. PASOTO SG, MENDONCA BB, BONFA E: Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus 2002; 11: 175-80.
14. SILVA CAA, LEAL MM, LEONE C et al.: Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus 2002; 11: 419-25.
15. CABRAL DE SOUSA D, DAS CHAGAS MEDEIROS MM, TRINDADE VIANA VS, SALANI MOTA RM: Anti-corpus luteum antibody and menstrual irregularity in patients with systemic lupus erythematosus and Hashimoto's thyroiditis. Lupus 2005; 14: 618-24.
16. BRUNNER HI, BISHNOI A, HARRON AC et al.: Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus 2006; 15:198-206.
17. SILVA CA, HILARIO MO, FEBRONIO MV et al.: Risk factors for amenorrhea in juvenile systemic lupus erithematosus. Lupus 2007; 16: 531-6.
18. SILVA CA, BRUNNER HI: Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus. Lupus 2007; 16: 593-9.
19. MOK CC, LAU CS, WONG RW: Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998; 41:831-7.
20. WANG CL, WANG F, BOSCO JJ: Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995; 4: 11-4.
21. MONCAYO-NAVEDA H, MONCAYO R, BENZ R, WOLF A, LAURITZEN C: Organ-specific antibodies against ovary in patients with systemic lupus erythematosus. Am J Obstet Gynecol 1989; 160: 1227-9.
22. PASOTO SG, VIANA VS, MENDONCA BB, YOSHINARI NH, BONFA E: Anti-corpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J Rheumatol 1999; 26: 1087-93.
23. SHOENFELD Y, BLANK M: Autoantibodies associated with reproductive failure. Lupus 2004; 13: 643-8.
24. CHROUSOS GP, TORPY DJ, GOLD PW: Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. Ann Intern Med 1998; 129: 229-40.
25. SAKETOS M, SHARMA N, SANTORO NF: Suppression of the hypothalamic-pituitary-ovarian axis in normal women by glucocorticoids. Biol Reprod 1993; 49: 1270-6.
26. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1992; 25: 1271-7.
27. BOMBARDIERI S, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
28. IVANOVA AV, SHARDINA LA, BENEDIKTOV II: Gonadotrophic and sex hormones in women with systemic lupus erythematosus. Revmatologiia 1989; 1: 3-8.
29. ARNALICH F, BENITO URBINA S, GONZALES GANCEDO P, IGLESIAS E, DE MIGUEL E, GIJON-BANOS J: Inadequate production of the progesterone in women with systemic lupus erythematosus. Br J Rheumatol 1992; 31: 247-51.
30. BENITO URBINA S, HUARTE LOZA E, GIJON BANOS J, ARNALICH FERNANDEZ F: Hormonal changes in fertile women with quiescent systemic lupus erythematosus. An Med Interna 1995; 12: 221-4.
31. MUNOZ JA, GIL A, LOPEZ-DUPLA JM, VAZGUEZ JJ, GONZALES GANCEDO P: Sex hormones in chronic systemic lupus erythematosus. Ann Med Interne 1994; 145: 459-63.
32. ALEKBEROVA ZS, FOLOMEEV MY, POLYNTSEV IV: The role of estrogen-androgen imbalance in rheumatic diseases. Ter Arkh 1990; 62: 17-21.
33. LAHITA RG: Sex hormones and systemic lupus erythematosus. Rheum Dis Clin North Am 2000; 26: 951-68.
34. CUTOLO M, SULLI A, CAPELLINO S et al.: Sex hormones on the immune system: basic and clinical aspects in autoimmunity. Lupus 2004; 13: 635-8.
35. CUTOLO M, CAPELLINO S, SULLI A et al.: Estrogens and autoimmune diseases. Ann N Y Acad Sci 2006; 1089: 538-47.
36. FOLOMEEV M, DOUGADOS M, BEAUNE J et al.: Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus 1992; 1: 191-5.
37. LAHITA RG: Sex steroids and SLE: Metabolism of androgens to estrogens [Editorial]. Lupus 1992; 1: 125-7.
38. LAHITA RG: The importance of estrogens in systemic lupus erythematosus. Clin Immunol Immunopathol 1992; 63: 17-8.
39. LAHITA RG, BRADLOW HL, KUNKEL HG, FISHMAN J: Increased 16-hydroxylation of estradiol in systemic lupus erythematosus. J Clin Endocrinol Metab 1981; 53: 174-8.
40. JIMENA P, AGUIRRE MA, LOPEZ-CURBELO A, DE ANDRES M, GARCIA-COURTAY C, CUADRADO MJ: Prolactin levels in patients with systemic lupus erythematosus: a case controlled study. Lupus 1998; 7: 383-6.
41. NEIDHART M: Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune progress in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 1996; 23: 476-81.
42. OSTENDORF B, FISCHER R, SANTEN R, SCHMITZ-LINNEWEBER B, SPECKER C, SCHNEIDER M: Hyperprolactinemia in systemic lupus erythematosus. Scand J Rheumatol 1996; 25: 97-102.
43. PAUZNER R, UROWITZ MB, GLADMAN DD, GOUGH JM: Prolactin in systemic lupus erythematosus. J Rheumatol 1994; 21: 2064-7.
44. SUGIURA K, MURO Y, WATANABE A, TOMITA Y: A case of systemic lupus erythematosus: continued association of circulating prolactin levels with disease activity over a 4-year follow-up period. Mod Rheumatol 2005; 15: 220-2.
45. BLANCO FAVELA F, QUINTAL-ALVAREZ G, LEANOS-MIRANDA A: Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power. J Rheumatol 1999; 26: 55-9.
46. JARA LJ, GOMEZ-SANCHEZ C, SILVEIRA LH, MARTINEZ-OSUNA P, VASEY FB, ESPINOZA LR: Hyperprolactinemia in systemic lupus erythematosus: association with disease activity. Am J Med Sci 1992; 303: 222-6.
47. CÁRDENAS-MONDRAGÓN G, ULLOA-AGUIRRE A, ISORDIA-SALAS I, GOFFIN V, LEAÑOS-MIRANDA A: Elevated serum bioactive prolactin concentrations in patients with systemic lupus erythematosus are associated with disease activity as disclosed by homologous receptor bioassays. J Rheumatol 2007; 34: 1514-21.
48. ZIETZ B, REBER T, OERTEL M, GLÜCK T, SCHÖLMERICH J, STRAUB RH: Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedione, cortisol, or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor. J Rheumatol 2000; 27: 911-8.
49. KÖLLER MD, TEMPL E, RIEDL M et al.: Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus. Ann Rheum Dis 2004; 63: 1677-80.
50. LADO-ABEAL J, RODRIGUES-ARNAO J, NEWELL-PRICE JD et al.: Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgens levels. J Clin Endocrinol Metab 1998; 83: 3083-8.